COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCL

Glofitamab plus R-CHOP in patients with high-risk LBCL: a Phase II trialПодробнее

Preliminary results from NP40126: Glofitamab and R-CHOP in NHLПодробнее

Glofitamab as a single agent in heavily pretreated patients with DLBCLПодробнее

The benefits of glofitamab in R/R DLBCL post-CAR-T therapyПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in patients with high-risk DLBCLПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase Ib Trial of Glofitamab Plus Pola-R-CHP in DLBCLПодробнее

Phase II study of glofitamab in patients with R/R LBCLПодробнее

How the treatment landscape of DLBCL is changing: R-CHOP vs pola-R-CHPПодробнее

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCLПодробнее

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?Подробнее

Glofitamab step-up dosing in R/R MCLПодробнее

Glofitamab and obinutuzumab in r/r MCLПодробнее

Glofitamab and polatuzumab vedotin in DLBCLПодробнее

Bispecific antibodies in NHL: current insights and ongoing studiesПодробнее

Smart Stop: Moving away from R-CHOP in DLBCLПодробнее

Dr. Tilly Discusses Study of POLA-R-CHP in DLBCLПодробнее

Pola-R-CHP vs R-CHOEP in young patients with high-risk DLBCLПодробнее

Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphomaПодробнее

Glofitamab in R/R DLBCL: updated safety and efficacy dataПодробнее

POLARIX trial: Is Pola-R-CHP effective and safe in elderly patients with DLBCL?Подробнее

POLARIX Trial and Polatuzumab in Frontline Chemotherapy for DLBCL - 2024 Blood Cancer OncTalkПодробнее